KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $628.5 million.

  • West Pharmaceutical Services' Cash & Equivalents rose 2803.01% to $628.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $628.5 million, marking a year-over-year increase of 2803.01%. This contributed to the annual value of $484.6 million for FY2024, which is 4324.86% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Cash & Equivalents is $628.5 million, which was up 2803.01% from $509.7 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Cash & Equivalents peaked at $898.6 million during Q3 2023, and registered a low of $404.2 million during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $667.7 million (2022), whereas its average is $659.0 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Cash & Equivalents soared by 4425.89% in 2021 and then plummeted by 4537.06% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Cash & Equivalents (Quarter) stood at $762.6 million in 2021, then increased by 17.27% to $894.3 million in 2022, then fell by 4.52% to $853.9 million in 2023, then plummeted by 43.25% to $484.6 million in 2024, then grew by 29.69% to $628.5 million in 2025.
  • Its Cash & Equivalents was $628.5 million in Q3 2025, compared to $509.7 million in Q2 2025 and $404.2 million in Q1 2025.